AR051792A1 - Compuestos de aminobenzofenona triazol sustituidos - Google Patents
Compuestos de aminobenzofenona triazol sustituidosInfo
- Publication number
- AR051792A1 AR051792A1 ARP050105193A ARP050105193A AR051792A1 AR 051792 A1 AR051792 A1 AR 051792A1 AR P050105193 A ARP050105193 A AR P050105193A AR P050105193 A ARP050105193 A AR P050105193A AR 051792 A1 AR051792 A1 AR 051792A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino
- hydroxyalkyl
- hydroxy
- alkyl
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical group C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 title 1
- -1 amino ureido, thioureido Chemical group 0.000 abstract 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 abstract 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004758 (C1-C4) alkoxyimino group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 229910003204 NH2 Inorganic materials 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- PSAGVOBYEMLIOJ-UHFFFAOYSA-N [4-(2-aminoanilino)-2-chlorophenyl]-[5-[1-(2-hydroxyethyl)triazol-4-yl]-2-methylphenyl]methanone Chemical compound CC1=CC=C(C=2N=NN(CCO)C=2)C=C1C(=O)C(C(=C1)Cl)=CC=C1NC1=CC=CC=C1N PSAGVOBYEMLIOJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Composicion farmacéutica y uso para preparar medicamentos para tratar trastornos inflamatorios u oftálmicos, cáncer, asma, alergia, artritis, entre otras enfermedades. Reivindicacion 1: Una compuesto de la formula general (1) o (2); en las cuales: R1 es metilo, cloro, bromo, o metoxi; R2 es cloro o metilo; R3 representa alquilo C1-6, alquenilo C2-6, alquinilo C2-6, hidroxialquilo C1-6, haloalquilo C1-6, alcoxi C1-6, alcoxicarbonilo, C1-6, amino C1-6 ureido, tioureido, alquilcarboniloxi C1-6, alquilcarbonilo C1-6, alcoxicarboniloxi C1-6, alcoxisulfoniloxi C1-6, alcoxicarbamoilo C1-6, o aminocarbonilo C1-6; cada uno de los cuales está opcionalmente sustituido con uno o más, sustituyentes iguales o diferentes seleccionados del grupo que consiste en halogeno, hidroxi mercapto, trifluormetilo, ciano, carboxi, CONH2, nitro, oxo, -S(O)2NH2, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, hidroxialquilo C1-4, haloalquilo C1-6, alcoxi C1-4, alcoxicarbonilo C1-4, ureido, tiureido, alquilcarboniloxi C1-4, alcoxicarboniloxi C1-4, alcoxisulfoniloxi C1-4, alcoxicarbamoilo C1-4, aminocarbonilo C1-4, alquiltio C1-4, cicloalquilo C3-6, cicloalquenilo C3-6, amino, imino, aminosulfonilo C1-4, aminocarboniloxi C1-4, alquilsulfonilamino C1-4, alcoxiimino C1-4, alquilcarbonilamino C1-4, alquilsulfonilo C1-4, heteroarilo C1-6, heterocicloalquilo C1-6, o heterocicloalquenilo C2-6; donde dicho alquilo C1-4, alquenilo C2-4, alquinilo C2-4, hidroxialquilo C1-4, haloalquilo C1-6, alcoxi C1-4, alcoxicarbonilo C1-4, ureido, tiureido, alquilcarboniloxi C1-4, alcoxicarboniloxi C1-4, alcoxisulfoniloxi C1-4, alcoxicarbamoilo C1-4, aminocarbonilo C1-4, alquiltio C1-4, cicloalquilo C3-6, cicloalquenilo C3-6, amino, imino, aminosulfonilo C1- 4, aminocarboniloxi C1-4, alquilsulfonilamino C1-4, alcoxiimino C1-4, alquilcarbonilamino C1-4, alquilsulfonilo C1-4, heteroarilo C1-6, heterocicloalquilo C1-6, o heterocicloalquenilo C2-6; están opcionalmente adicionalmente sustituidos con uno o más sustituyentes iguales o diferentes seleccionados del grupo que consiste en halogeno, hidroxi, -NH2, mercapto, trifluormetilo, ciano, carboxi, CONH2, nitro, oxo, -S(O)2NH2, alquilo C1-4, o hidroxialquilo C1-4; o R3 representa hidrogeno, hidroxi o carboxi; R4, R5, R6, R7, y R8 independientemente uno del otro representan cada uno hidrogeno, halogeno, NH2, hidroxi, trifluormetilo, metoxi, etoxi, ciano, acetilo, acetamido, metilo o etilo; con la condicion de que el compuesto no sea [4-(2- aminofenil)amino)-2-clorofenil]-[2-metil-5-[1-2-[(tetrahidro-2H-piran-2-il)oxi]etil]-1H-1,2,3-triazol-4-il]-fenil]-metanona o [4-[(2-aminofenil)amino]-2-clorofenil]-[5-[1-(2-hidroxietil)-1H-1,2,3-triazol-4-il]-2-metilfenil]-metanona; o una sal, solvato o éster del mismo farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63500004P | 2004-12-13 | 2004-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051792A1 true AR051792A1 (es) | 2007-02-07 |
Family
ID=37715934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105193A AR051792A1 (es) | 2004-12-13 | 2005-12-12 | Compuestos de aminobenzofenona triazol sustituidos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8293772B2 (es) |
| EP (1) | EP1828148B1 (es) |
| JP (1) | JP5015005B2 (es) |
| KR (1) | KR101260236B1 (es) |
| CN (1) | CN101115728B (es) |
| AR (1) | AR051792A1 (es) |
| AT (1) | ATE455768T1 (es) |
| AU (1) | AU2005316034B2 (es) |
| BR (1) | BRPI0518993A2 (es) |
| CA (1) | CA2590479A1 (es) |
| DE (1) | DE602005019093D1 (es) |
| DK (1) | DK1828148T3 (es) |
| ES (1) | ES2341473T3 (es) |
| HR (1) | HRP20100225T1 (es) |
| IL (1) | IL183513A0 (es) |
| MX (1) | MX2007006739A (es) |
| NO (1) | NO20073574L (es) |
| PL (1) | PL1828148T3 (es) |
| PT (1) | PT1828148E (es) |
| RU (1) | RU2394818C2 (es) |
| UA (1) | UA90698C2 (es) |
| WO (1) | WO2006063585A1 (es) |
| ZA (1) | ZA200704809B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2226316B1 (en) | 2002-05-30 | 2016-01-13 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| JP2009541286A (ja) * | 2006-06-21 | 2009-11-26 | ハマースミス・イメイネット・リミテッド | 化学的方法及び装置 |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| KR100932093B1 (ko) | 2006-09-27 | 2009-12-16 | 주식회사종근당 | 미세소관 형성 저해제로서 유용한 벤조페논 유도체 |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| CA2706839C (en) * | 2007-12-18 | 2015-10-20 | Actelion Pharmaceuticals Ltd | Aminotriazole derivatives as alx agonists |
| WO2009119980A2 (ko) * | 2008-03-26 | 2009-10-01 | 주식회사 종근당 | 미세소관 형성 저해제로서 유용한 벤조페논 티아졸 유도체 및 이의 제조 방법 |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| ES2927660T3 (es) | 2008-06-16 | 2022-11-10 | Univ Tennessee Res Found | Compuestos para el tratamiento del cáncer |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US20120322776A1 (en) | 2009-12-22 | 2012-12-20 | Leo Pharma A/S | Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants |
| PL2515874T3 (pl) | 2009-12-22 | 2015-01-30 | Leo Pharma As | Nanokryształy jednowodnego kalcypotriolu |
| ES2452872T3 (es) | 2009-12-22 | 2014-04-03 | Leo Pharma A/S | Composición farmacéutica que comprende una mezcla solvente y un derivado o análogo de vitamina D |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| JP5879273B2 (ja) | 2010-03-01 | 2016-03-08 | ジーティーエックス・インコーポレイテッド | 癌を処置するための化合物 |
| KR101666759B1 (ko) * | 2015-08-06 | 2016-10-18 | 경북대학교 산학협력단 | 1-벤조피란메틸-1h-1,2,3-트리아졸 유도체 및 이의 용도 |
| CN106632285B (zh) * | 2016-11-23 | 2019-11-01 | 河南师范大学 | 一种齐多夫定-1,2,3-三氮唑类化合物的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1709907A3 (ru) * | 1988-01-07 | 1992-01-30 | Е.И.Дюпон Де Немур Энд Компани (Фирма) | Способ получени азолов |
| GB9701453D0 (en) * | 1997-01-24 | 1997-03-12 | Leo Pharm Prod Ltd | Aminobenzophenones |
| KR20020033733A (ko) | 1999-07-16 | 2002-05-07 | 룬딩 에른스트 | ＩＬ-1β 및 ＴＮＦ-α 억제제로서의 아미노벤조페논 |
| SI1210320T1 (en) | 1999-07-16 | 2005-02-28 | Leo Pharma A/S | Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| EP1202959B1 (en) | 1999-07-16 | 2004-09-29 | Leo Pharma A/S | Aminobenzophenones as inhibitors of il-1-beta and tnf-alpha |
| RU2238933C2 (ru) | 1999-07-16 | 2004-10-27 | Лео Фармасьютикал Продактс Лтд.А/С (Левенс Кемиске Фабрик Продукционсактиесельскаб) | Аминобензофеноны как ингибиторы ил-1 бэта и tnf-альфа |
| PL353645A1 (en) | 1999-07-16 | 2003-12-01 | Leo Pharma A/Sleo Pharma A/S | Novel aminobenzophenones |
| HUP0203813A3 (en) * | 1999-12-06 | 2008-03-28 | Leo Pharma As | Aminobenzophenones as inhibitors of il-1betha and tnf-alpha, pharmaceutical compositions containing them and their use |
| WO2001090074A2 (en) | 2000-05-22 | 2001-11-29 | Leo Pharma A/S | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| GB0107368D0 (en) | 2001-03-23 | 2001-05-16 | Novartis Ag | Organic compounds |
| AU2002338286A1 (en) | 2001-04-10 | 2002-10-28 | Leo Pharma A/S | Novel aminophenyl ketone derivatives |
| IL160442A0 (en) | 2001-08-28 | 2004-07-25 | Leo Pharma As | Novel aminobenzophenones |
| US20060058380A1 (en) | 2002-12-20 | 2006-03-16 | Ottosen Erik R | Novel aminobenzophenone compounds |
| US7977387B2 (en) * | 2003-07-24 | 2011-07-12 | Leo Pharma A/S | Aminobenzophenone compounds |
| US20090313239A1 (en) | 2008-06-16 | 2009-12-17 | Microsoft Corporation | Adaptive Visual Similarity for Text-Based Image Search Results Re-ranking |
-
2005
- 2005-11-28 ZA ZA200704809A patent/ZA200704809B/xx unknown
- 2005-11-28 PL PL05804019T patent/PL1828148T3/pl unknown
- 2005-11-28 PT PT05804019T patent/PT1828148E/pt unknown
- 2005-11-28 KR KR1020077015959A patent/KR101260236B1/ko not_active Expired - Fee Related
- 2005-11-28 AT AT05804019T patent/ATE455768T1/de active
- 2005-11-28 WO PCT/DK2005/000757 patent/WO2006063585A1/en not_active Ceased
- 2005-11-28 DK DK05804019.7T patent/DK1828148T3/da active
- 2005-11-28 RU RU2007126648/04A patent/RU2394818C2/ru not_active IP Right Cessation
- 2005-11-28 HR HR20100225T patent/HRP20100225T1/hr unknown
- 2005-11-28 MX MX2007006739A patent/MX2007006739A/es active IP Right Grant
- 2005-11-28 AU AU2005316034A patent/AU2005316034B2/en not_active Ceased
- 2005-11-28 ES ES05804019T patent/ES2341473T3/es not_active Expired - Lifetime
- 2005-11-28 EP EP05804019A patent/EP1828148B1/en not_active Expired - Lifetime
- 2005-11-28 BR BRPI0518993-4A patent/BRPI0518993A2/pt not_active IP Right Cessation
- 2005-11-28 UA UAA200707890A patent/UA90698C2/ru unknown
- 2005-11-28 JP JP2007545836A patent/JP5015005B2/ja not_active Expired - Fee Related
- 2005-11-28 CA CA002590479A patent/CA2590479A1/en not_active Abandoned
- 2005-11-28 DE DE602005019093T patent/DE602005019093D1/de not_active Expired - Lifetime
- 2005-11-28 CN CN2005800480385A patent/CN101115728B/zh not_active Expired - Fee Related
- 2005-12-02 US US11/292,064 patent/US8293772B2/en not_active Expired - Fee Related
- 2005-12-12 AR ARP050105193A patent/AR051792A1/es not_active Application Discontinuation
-
2007
- 2007-05-29 IL IL183513A patent/IL183513A0/en unknown
- 2007-07-10 NO NO20073574A patent/NO20073574L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0518993A2 (pt) | 2008-12-23 |
| EP1828148B1 (en) | 2010-01-20 |
| CN101115728A (zh) | 2008-01-30 |
| EP1828148A1 (en) | 2007-09-05 |
| US20060128766A1 (en) | 2006-06-15 |
| AU2005316034A1 (en) | 2006-06-22 |
| JP5015005B2 (ja) | 2012-08-29 |
| NO20073574L (no) | 2007-07-10 |
| DK1828148T3 (da) | 2010-05-17 |
| MX2007006739A (es) | 2007-08-02 |
| CA2590479A1 (en) | 2006-06-22 |
| WO2006063585A1 (en) | 2006-06-22 |
| CN101115728B (zh) | 2012-12-19 |
| KR20070095945A (ko) | 2007-10-01 |
| RU2394818C2 (ru) | 2010-07-20 |
| ZA200704809B (en) | 2008-08-27 |
| RU2007126648A (ru) | 2009-01-20 |
| AU2005316034B2 (en) | 2012-01-19 |
| US8293772B2 (en) | 2012-10-23 |
| JP2008523115A (ja) | 2008-07-03 |
| PL1828148T3 (pl) | 2010-08-31 |
| ES2341473T3 (es) | 2010-06-21 |
| KR101260236B1 (ko) | 2013-05-06 |
| UA90698C2 (en) | 2010-05-25 |
| HRP20100225T1 (hr) | 2010-07-31 |
| PT1828148E (pt) | 2010-05-04 |
| ATE455768T1 (de) | 2010-02-15 |
| DE602005019093D1 (de) | 2010-03-11 |
| IL183513A0 (en) | 2007-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051792A1 (es) | Compuestos de aminobenzofenona triazol sustituidos | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
| AR082825A2 (es) | Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios | |
| SE0302486D0 (sv) | Novel compounds | |
| AR106744A2 (es) | Formas cristalinas de un compuesto de bifenilo | |
| PA8575401A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso | |
| PE20171242A1 (es) | Dispersiones solidas extruidas por fusion que contienen un agente inductor de apoptosis | |
| CL2011002706A1 (es) | Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras. | |
| CO6270241A2 (es) | Algunos derivados de 2-pirazinona procesos para su preparacion composiciones farmaceuticas que los contiene y su uso en terapia | |
| SE0302487D0 (sv) | Novel compounds | |
| PE20070121A1 (es) | 2,4-diamino-pirimidinas como inhibidores de aurora | |
| CL2012001328A1 (es) | Compuestos derivados de (4,5,6,7-tetrahidro-1h-indazol-3-il)-1h-indol, inhibidores de itk; composicion farmaceutica; utiles en el tratamiento de enfermedades inflamatorias, tales como artritis reumatoidea, alergias, enfermedades autoinmunes, entre otras. | |
| AR056764A1 (es) | Aminopirimidinas utiles como inhibidores de quinasa | |
| ATE369370T1 (de) | Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren | |
| AR046615A1 (es) | Pirrolidinas 3-(benzoil)-n-aciladas, como inhibidores de 11-beta-hsd1, utiles en el tratamiento de desordenes metabolicos | |
| BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
| DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR041250A1 (es) | Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa | |
| AR046616A1 (es) | Piperidinas sustituidas utiles en el tratamiento de sindrome metabolico | |
| AR063637A1 (es) | Inhibidores de las quinasas y metodos para su utilizacion | |
| AR049578A1 (es) | Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas | |
| PE20141148A1 (es) | Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| AR062501A1 (es) | Composiciones terapeuticas | |
| AR046942A1 (es) | Arilpirazoles sustituidos, un procedimiento para su preparacion, composiciones farmaceuticas o veterinarias que los contienen como principio activo y su uso en la fabricacion de un medicamento parasiticida humano o animal. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |